316 related articles for article (PubMed ID: 15077254)
21. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
22. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
[TBL] [Abstract][Full Text] [Related]
23. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.
Spoorenberg A; van Tubergen A; Landewé R; Dougados M; van der Linden S; Mielants H; van de Tempel H; van der Heijde D
Rheumatology (Oxford); 2005 Jun; 44(6):789-95. PubMed ID: 15757962
[TBL] [Abstract][Full Text] [Related]
24. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study.
Pavy S; Brophy S; Calin A
J Rheumatol; 2005 Jan; 32(1):80-5. PubMed ID: 15630730
[TBL] [Abstract][Full Text] [Related]
25. Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires.
Van Tubergen A; Debats I; Ryser L; Londoño J; Burgos-Vargas R; Cardiel MH; Landewé R; Stucki G; Van Der Heijde D
Arthritis Rheum; 2002 Jun; 47(3):242-8. PubMed ID: 12115152
[TBL] [Abstract][Full Text] [Related]
26. Validation of the Tunisian versions of Bath Ankylosing Spondylitis Functional Index (BASFI) and Disease Activity Index (BASDAI).
Kchir MM; Hamdi W; Kochbati S; Azzouz D; Daoud L; Saadellaoui K; Ghannouchi MM; Kaffel D; Ben Hamida A; Zouari B
Tunis Med; 2009 Aug; 87(8):527-30. PubMed ID: 20180357
[TBL] [Abstract][Full Text] [Related]
27. The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity.
Cronstedt H; Waldner A; Stenström CH
Scand J Rheumatol Suppl; 1999; 111():1-9. PubMed ID: 10503553
[TBL] [Abstract][Full Text] [Related]
28. Six months open label trial of leflunomide in active ankylosing spondylitis.
Haibel H; Rudwaleit M; Braun J; Sieper J
Ann Rheum Dis; 2005 Jan; 64(1):124-6. PubMed ID: 15608310
[TBL] [Abstract][Full Text] [Related]
29. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
30. Mental health status and leisure-time physical activity contribute to fatigue intensity in patients with spondylarthropathy.
Da Costa D; Dritsa M; Ring A; Fitzcharles MA
Arthritis Rheum; 2004 Dec; 51(6):1004-8. PubMed ID: 15593104
[TBL] [Abstract][Full Text] [Related]
31. Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish.
Pedersen OB; Hansen GO; Svendsen AJ; Ejstrup L; Junker P
Scand J Rheumatol; 2007; 36(1):22-7. PubMed ID: 17454931
[TBL] [Abstract][Full Text] [Related]
32. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
33. Costs and quality of life of patients with ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
[TBL] [Abstract][Full Text] [Related]
34. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis.
van Tubergen A; Coenen J; Landewé R; Spoorenberg A; Chorus A; Boonen A; van der Linden S; van der Heijde D
Arthritis Rheum; 2002 Feb; 47(1):8-16. PubMed ID: 11932872
[TBL] [Abstract][Full Text] [Related]
35. Assessing back pain: does the Oswestry Disability Questionnaire accurately measure function in ankylosing spondylitis?
O'Shea FD; Riarh R; Anton A; Inman RD
J Rheumatol; 2010 Jun; 37(6):1211-3. PubMed ID: 20395642
[TBL] [Abstract][Full Text] [Related]
36. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments.
Østensen M; Fuhrer L; Mathieu R; Seitz M; Villiger PM
Ann Rheum Dis; 2004 Oct; 63(10):1212-7. PubMed ID: 15361373
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy.
Claudepierre P; Sibilia J; Goupille P; Flipo RM; Wendling D; Eulry F; Clerc D; Berthelot JM; Vergne P; Roudot-Thoraval F; Larget-Piet B; Chevalier X
J Rheumatol; 1997 Oct; 24(10):1954-8. PubMed ID: 9330938
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging assessment of spinal inflammation in patients treated for ankylosing spondylitis.
Treitl M; Korner M; Becker-Gaab C; Tryzna M; Rieger J; Pfeifer KJ; Reiser MF; Wirth S
J Rheumatol; 2008 Jan; 35(1):126-36. PubMed ID: 18061979
[TBL] [Abstract][Full Text] [Related]
39. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.
Gladman DD; Inman RD; Cook RJ; Maksymowych WP; Braun J; Davis JC; Landewé RB; Mease P; Brandt J; Vargas RB; Chandran V; Helliwell P; Kavanaugh A; O'Shea FD; Khan MA; Pipitone N; Rahman P; Reveille JD; Stone MA; Taylor W; Veale DJ; van der Heijde D
J Rheumatol; 2007 Aug; 34(8):1740-5. PubMed ID: 17659754
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
